Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NanoViricides - Nanobiotechnology -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (736)	1/5/2018 1:16:19 PM
From: donpat	Read Replies (3) \| Respond to of 1220

FDA Grants ExThera Medical’s Seraph® 100 Blood Filter Expedited Access Pathway (EAP) Designation The EAP should make Seraph available to clinicians more quickly, satisfying the ‘unmet need’ for improved treatments for drug-resistant infections Martinez, CA. – August 30, 2017 – ExThera Medical Corporation, the leading developer of innovative filtration devices for removing pathogens from whole blood, today announced that the U.S. Food and Drug Administration (FDA) has granted ExThera’s Seraph® 100 Blood Filter (Seraph) the agency’s Expedited Access Pathway (EAP) designation. Seraph’s initial indication for use will be ‘as an adjunctive treatment for bacteremia in addition to antibiotics for patients receiving hemodialysis when the source of the infection is a heparin- or heparan sulfate-binding bacteria, including antibiotic resistant bacteria MRSA, VRE, ESBL, CRE, and MRSE.’ extheramedical.com